Microcap Ledger Aligos Therapeutics, Inc. $ALGS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
What the company doesAI summary of filing
Aligos Therapeutics is a clinical-stage biotechnology company developing drug candidates for liver diseases and viral infections. The company's pipeline includes pevifoscorvir sodium for chronic hepatitis B virus infection (currently in Phase 2), ALG-055009 for metabolic dysfunction-associated steatohepatitis and obesity (completed Phase 2a), ALG-097558 for coronavirus infections (in Phase 2), and preclinical programs. The company is pre-revenue and has not generated product sales revenue. Aligos funds development through research collaborations, government grants, and capital raises, with plans to pursue independent development and commercialization in select markets while exploring licensing and partnership opportunities. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $2.83M | −$24.54M | −$48.08M | $30.38M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $2.19M | −$24.19M | −$82.50M | $18.30M | [10-K 2026-03-05] |
| FY ended Dec 2024 | $3.61M | −$131.21M | −$80.74M | $37.00M | [10-K 2026-03-05] |
- Quarterly cash burn
- −$24.04M
- Cash runway Estimate
- ~3.8 months
Capital structure and dilution
- Shelf registration
- S-3 filed 2025-03-27; declared effective 2025-04-03 [S-3 2025-03-27]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-15 | 8-K | Material agreement entered |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-06-26 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-24 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-29 | DEF 14A | Proxy statement |
| 2026-04-21 | 8-K | Material agreement entered |
| 2026-04-14 | 8-K | Other events |
Alerts for $ALGS
Email me when Aligos Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.